ReviewEye and vision (London, England)2019
Hydrus microstent implantation for surgical management of glaucoma: a review of design, efficacy and safety.
Review in Eye and vision (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- HydrusJournal of clinical medicine · 2026Article
- Retrospective Analysis of 5-Year Outcomes with the Hydrus Microstent in Combination with Cataract Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Effectiveness and Safety of Combined Ab-Interno Canaloplasty and Microstent Implantation in Severe Glaucoma - A Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Efficacy of the novel MIGS implant Wistend compared to Kahook Dual Blade in the treatment of experimental ocular hypertension in rabbits.Scientific reports · 2025Article
- Imaging of aqueous outflow in health and glaucoma. Justifying the re-direction of aqueous.Eye (London, England) · 2025Review
- Comparison of the Intraocular Pressure-Lowering Effect of Minimally Invasive Glaucoma Surgery (MIGS) iStent Inject W and Hydrus-The 12-Month Real-Life Data.Diagnostics (Basel, Switzerland) · 2025Article
- Retrospective Study of 2-year Clinical Outcomes of Combination Ab-Interno Canaloplasty and a Microstent Compared to Ab-Interno Canaloplasty in Cataract Surgery Patients.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Efficacy and Safety of Cataract Surgery Combined with Ab Interno Canaloplasty and Micro-Trabecular Bypass Stent Surgery in Open-Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Surgical Synergy in Primary Open-Angle Glaucoma: Assessing Safety and Efficacy of Hydrus, iStent, and Gonioscopy-Assisted Transluminal Trabeculotomy in Glaucoma Management.Journal of clinical medicine · 2024Review
- Effectiveness and biocompatibility of a novel Schlemm's canal microstent for glaucoma management.Scientific reports · 2024Article
- Mid-term real world outcomes of the HydrusEye (London, England) · 2024Article
- Evaluating the effect of pulse energy on femtosecond laser trabeculotomy (FLT) outflow channels for glaucoma treatment in human cadaver eyes.Lasers in surgery and medicine · 2024Article
- Therapeutic strategies for glaucoma and optic neuropathies.Molecular aspects of medicine · 2023Review
- Minimally Invasive Glaucoma Surgery: A Review of the Literature.Vision (Basel, Switzerland) · 2023Review
- Position of the ISTENT InjectJournal of clinical medicine · 2023Article
- Hydrus Microstent implantation with OMNI Surgical System Ab interno canaloplasty for the management of open-angle glaucoma in phakic patients refractory to medical therapy.American journal of ophthalmology case reports · 2023Article
- Comparison of Safety and Efficacy of Hydrus and iStent Combined with Phacoemulsyfication in Open Angle Glaucoma Patients: 24-Month Follow-Up.International journal of environmental research and public health · 2023Article
- The PreserFlo MicroShunt in the Context of Minimally Invasive Glaucoma Surgery: A Narrative Review.International journal of environmental research and public health · 2023Review
- Spotlight on Schlemm's Canal MicroStent Injection in Patients with Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Advances in Excimer Laser Trabeculostomy within the Landscape of Minimally-Invasive Glaucoma Surgery.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the advent of microinvasive glaucoma surgery (MIGS), the spectrum of modalities available to manage patients with this chronic and heterogeneous condition has broadened. Despite its novelty however, there has been a rapid evolution in the development of a multitude of devices, each targeting a structure along the aqueous drainage pathway. A growing body of evidence has demonstrated IOP and medication burden reduction, and a more favorable safety profile with MIGS procedures in contrast to traditional incisional surgeries. Among the array of MIGS, the Hydrus® Microstent (Ivantis, Inc., Irvine, CA) is a recent FDA approved device, designed to bypass the trabecular meshwork and provide a scaffold for Schlemm's canal. The objective of this article is to review the Hydrus from conception to clinical use, and present data on its efficacy and safety to date. The available literature has shown promise, however inherent to all novel devices, only long-term monitoring will ensure sustained IOP control and an acceptable safety profile. Surgical advancements in glaucoma have revolutionized the field, and continued research and development will establish these approaches in clinical treatment algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.